Grant: Alliance Grants
University of Waterloo
$50,000.00
Improvement of the Frequencer ability to treat COVID-19 patients who require airway clearance_x000d_ _x000d_
EF 2020-21
Résumé
Dymedso, a Canadian-based medical device SME specialized in pulmonary disease therapeutic and treatment equipment is a patented pioneer in using sound (acoustics) to treat patients requiring airway clearance such as Cystic Fibrosis COPD and the coronavirus family, SARS, MERS and naturally the COVID-19. The company's Frequencer® has FDA, Health Canada, European CE, and UL (North America, Europe, Australia, and New Zealand) approvals and has been used in hospitals since 2010 with an established base of more than 600 devices in operations around the globe.
Dymedso continues to explore ways to improve its product by conducting research aiming development products to treat wider range of patients requiring airway. The goal of Dymedso (Richard Boudreault) and the University of Waterloo (Yuri Leonenko) partnership is to investigate the possibilities to improve performance of Frequencer and improve the product's ability to treat COVID-19 patients who require airway clearance.
Currently Dymedso is increasing the supply of its devices to Montreal hospitals to treat COVID-19 patients. Most patients using the Frequencer will never require an ICU bed nor a ventilator.
Programme
Alliance Grants
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
550306-2020
Name nom
Leonenko, Yuri
Department département
Earth & Environmental Sciences
Organization id
33
Institution établissement
University of Waterloo
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2020
Award amount
50000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1900
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical engineering
Research subject fr
Génie biomédical
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
Improvement of the Frequencer ability to treat COVID-19 patients who require airway clearance_x000d_
_x000d_
Keyword
NSERC
Application summary
Dymedso, a Canadian-based medical device SME specialized in pulmonary disease therapeutic and treatment equipment is a patented pioneer in using sound (acoustics) to treat patients requiring airway clearance such as Cystic Fibrosis COPD and the coronavirus family, SARS, MERS and naturally the COVID-19. The company's Frequencer® has FDA, Health Canada, European CE, and UL (North America, Europe, Australia, and New Zealand) approvals and has been used in hospitals since 2010 with an established base of more than 600 devices in operations around the globe.
Dymedso continues to explore ways to improve its product by conducting research aiming development products to treat wider range of patients requiring airway. The goal of Dymedso (Richard Boudreault) and the University of Waterloo (Yuri Leonenko) partnership is to investigate the possibilities to improve performance of Frequencer and improve the product's ability to treat COVID-19 patients who require airway clearance.
Currently Dymedso is increasing the supply of its devices to Montreal hospitals to treat COVID-19 patients. Most patients using the Frequencer will never require an ICU bed nor a ventilator.